Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Malaria resulting from infection by Plasmodium falciparum.
Biomarker and diagnostic research for Plasmodium falciparum malaria has been reported in the published literature.
1 FDA-approved treatment is available for Plasmodium falciparum malaria, including ATOVAQUONE AND PROGUANIL HYDROCHLORIDE (MALARONE, approved 2000). An additional 1 compound holds orphan drug designation.
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
22 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, biologic therapy, and other interventions. Pipeline includes 2 PHASE4, 4 PHASE3, 6 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06923592](https://clinicaltrials.gov/study/NCT06923592) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
Common questions about Plasmodium falciparum malaria
MALARONE |
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE |
— |
2000 |
Available |
The following drugs have received orphan drug designation from the FDA for Plasmodium falciparum malaria. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Lariam | mefloquine HCL | Hoffmann-La Roche, Inc. | 1988 | 1996 | Withdrawn |
Gene therapy approaches for Plasmodium falciparum malaria have been reported in the published literature.
22 trials found
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar |
PHASE3 |
London School of Hygiene and Tropical Medicine |
RECRUITING |
[NCT05951595](https://clinicaltrials.gov/study/NCT05951595) | A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines | PHASE3 | University of Oxford | RECRUITING |
[NCT07036159](https://clinicaltrials.gov/study/NCT07036159) | A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months | PHASE2 | GlaxoSmithKline | RECRUITING |
[NCT06068530](https://clinicaltrials.gov/study/NCT06068530) | Mass Vaccine and Drug Administration, Bangladesh | PHASE4 | University of Oxford | RECRUITING |
[NCT06529237](https://clinicaltrials.gov/study/NCT06529237) | Malaria Molecular Surveillance in Mozambique (Phase 2) | — | Centro de Investigacao em Saude de Manhica | RECRUITING |
308 publications have been identified in PubMed for Plasmodium falciparum malaria. Kisho has analyzed 229 by research type. Research spans Basic Science / Preclinical (29%), Epidemiology / Natural History (20%), and Clinical Trial Publication (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 66 | 29% |
Disease patterns and progression | 45 | 20% |
Clinical study results | 41 | 18% |
Research summaries | 26 | 11% |
Patient case studies | 22 | 10% |
New treatment approaches | 16 | 7% |
Testing and diagnosis research | 11 | 5% |
Other research | 2 | 1% |
Huppertz F (2026). [PMID: 41084330](https://pubmed.ncbi.nlm.nih.gov/41084330/). *FEBS letters*. [Basic Science / Preclinical]
González-Castillo NI (2026). [PMID: 41352519](https://pubmed.ncbi.nlm.nih.gov/41352519/). *Microb Pathog*. [Review / Meta-Analysis]
Hajali TA (2026). [PMID: 42194890](https://pubmed.ncbi.nlm.nih.gov/42194890/). *J Clin Med*. [Diagnostic / Biomarker]
Tshilumba SM (2026). [PMID: 42188851](https://pubmed.ncbi.nlm.nih.gov/42188851/). *Trop Med Infect Dis*. [Epidemiology / Natural History]
Shi D (2026). [PMID: 41420060](https://pubmed.ncbi.nlm.nih.gov/41420060/). *Nature microbiology*. [Gene Therapy / Novel Therapeutics]
Juma E (2026). [PMID: 41152149](https://pubmed.ncbi.nlm.nih.gov/41152149/). *Br J Clin Pharmacol*. [Epidemiology / Natural History]
Nhama A (2026). [PMID: 42174576](https://pubmed.ncbi.nlm.nih.gov/42174576/). *Malar J*. [Review / Meta-Analysis]
Emerole K (2026). [PMID: 42199685](https://pubmed.ncbi.nlm.nih.gov/42199685/). *Trop Parasitol*. [Clinical Trial Publication]
Rajaonarimirana E (2026). [PMID: 41666420](https://pubmed.ncbi.nlm.nih.gov/41666420/). *Am J Trop Med Hyg*. [Basic Science / Preclinical]
Cassol C (2026). [PMID: 42263924](https://pubmed.ncbi.nlm.nih.gov/42263924/). *Travel Med Infect Dis*. [Case Report / Case Series]
AI-curated news mentioning Plasmodium falciparum malaria
Updated May 16, 2026
Recent research highlights a rise in imported Plasmodium vivax malaria cases in New York City, linked to demographic changes from recent migration. This study provides critical insights into the clinical trends and challenges posed by this resurgence.